Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization.
